Baxter International Inc(BAX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | S&P 500 | P/E | - | EPS (ttm) | -1.93 | Insider Own | 0.63% | Shs Outstand | 517.0M | Perf Week | -5.91% |
| Market Cap | 12.50B | Forward P/E | 11.85 | EPS next Y | -0.61% | Insider Trans | - | Shs Float | 513.7M | Perf Month | -12.42% |
| Enterprise Value | 19.18B | PEG | - | EPS next Q | 0.52 | Inst Own | 109.6% | Short Float | 4.66% | Perf Quarter | 19.05% |
| Income | -0.99B | P/S | 1.09 | EPS this Y | -7.07% | Inst Trans | 4.15% | Short Ratio | 3.68 | Perf Half Y | 33.96% |
| Sales | 11.47B | P/B | 2.01 | EPS next 5Y | -0.67% | ROA | -4.74% | Short Interest | 23.91M | Perf YTD | 26.53% |
| Book/sh | 12 | P/C | 5.81 | EPS past 3/5Y | 24.78% - | ROE | -14.31% | 52W High | -19.4% ($30.00) | Perf Year | 0.83% |
| Cash/sh | 4.16 | P/FCF | 15.34 | Sales past 3/5Y | -8.14% -0.75% | ROIC | -6.96% | 52W Low | 53.72% ($15.73) | Perf 3Y | -37.47% |
| Dividend Est. | $0.04 (0.16%) | EV/EBITDA | 12 | EPS Y/Y TTM | -632.85% | Gross Margin | 31.85% | Volatility(W/M) | 3.41% 2.77% | Perf 5Y | -70.12% |
| Dividend TTM | 0.04 | EV/Sales | 1.67 | Sales Y/Y TTM | 5.36% | Oper. Margin | 5.62% | ATR (14) | 0.84 | Perf 10Y | -46.37% |
| Dividend Ex-Date | 2026/8/28 | Quick Ratio | 1.32 | EPS Q/Q | 11.61% | Profit Margin | -8.63% | RSI (14) | 37.62 | Recom | 2.73 |
| Dividend Gr. 3/5Y | -23.25% -11.35% | Current Ratio | 1.95 | Sales Q/Q | 5.34% | SMA20 | -6.71% ($25.92) | Beta | 0.65 | Target Price | $27.6 |
| Payout | - | Debt/Eq | 1.43 | Earnings | 2026/7/30 | SMA50 | -2.8% ($24.88) | Rel Volume | 0.86 | Prev Close | $24.39 |
| Employees | 37500 | LT Debt/Eq | 1.29 | EPS/Sales Surpr. | 52.8% 5.88% | SMA200 | 18.26% ($20.45) | Avg Volume(3M) | 6.51M | Price | $24.18 |
| IPO | 1961/5/16 | Option/Short | Yes/Yes | Trades | 32583 | Volume | 5,622,604 | Change | -0.86% |
Company
BAX is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A U.S. medical device and pharmaceutical company, this global medical products firm manufactures IV (intravenous) solutions, infusion pumps, and hospital-grade medical products, supplying them to hospitals and healthcare facilities. Demand for essential hospital products provides a stable foundation for the business.
Over the past 1 year, roughly in the middle
19% below its 1-year high.
BAX has weak earning power
5.62% of revenue is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -7.1% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Would have changed by -37.5% if bought 5 years ago.
Tap to view numbers
The dividend is on the small side
Pays 0.16% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 109.6%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
PZLV 0.04%
MDEV 0.03%
IBD 0.02%
BLCV 0.02%
BDYN 0.02%It ranks #4 in the industry
Based on market cap of $13B.
BAX $13B PER -
ISRG $127B PER 41.3
BDX $48B PER 53.2
MDLN $43B PER 38.0
FAQ
What kind of company is BAX?
BAX belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of BAX?
The market cap of BAX is approximately $12.5B, ranking 812 within its sector.
Does BAX pay dividends?
BAX has a dividend yield of approximately 0.16%, with an annual dividend of $0.04.
What is the 52-week high and low for BAX?
BAX has recorded a 52-week high of $30.00 and a low of $15.73.
